Objective To evaluate the safety and durability of telitacicept treatment in patients with SLE by identifying the reasons for ...
Background Although the increased risk of cardiovascular disease in patients with SLE is well-documented, effective tools for risk stratification remain elusive. This study sought to explore the ...
Objective Biologics for systemic lupus erythematosus (SLE) demonstrate variable treatment responses across trials. We evaluated baseline biomarkers as predictors of response to guide personalised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results